STOCK TITAN

CRISPR Therapeutics: Orbis, Allan Gray report 4.7%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd reported beneficial ownership of 4,519,261 CRISPR Therapeutics AG common shares, equal to 4.7% of the class, with the ownership information dated September 30, 2026.

Orbis reported 4,501,782 shares and Allan Gray reported 17,479. Each reported sole voting and dispositive power over its respective shares, with no shared power. Although they filed together, neither represents that it is a member of a group under Section 13(d)(3), and each disclaims beneficial ownership of shares attributed to the other.

Aggregate shares beneficially owned 4,519,261 shares Reported for September 30, 2026
Percentage of class 4.7% Reported for September 30, 2026
Orbis shares beneficially owned 4,501,782 shares Orbis Investment Management Ltd; reported for September 30, 2026
Allan Gray shares beneficially owned 17,479 shares Allan Gray Australia Pty Ltd; reported for September 30, 2026
beneficial ownership regulatory
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
sole voting power regulatory
"Sole power to vote or to direct the vote"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive power regulatory
"Sole power to dispose or to direct the disposition"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Section 13(d)(3) regulatory
"member of a group for the purposes of Section 13(d)(3)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Are Orbis and Allan Gray part of a CRSP ownership group?

Neither entity represents that it is a member of a group under Section 13(d)(3), although they filed together. Each also disclaims beneficial ownership of shares reported by the other.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





H17182108

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



ORBIS INVESTMENT MANAGEMENT LTD
Signature:Matthew Gaarder
Name/Title:Attorney-in-Fact
Date:11/16/2026
Allan Gray Australia Pty Ltd
Signature:Matthew Gaarder
Name/Title:Attorney-in-Fact
Date:11/16/2026

Keep reading